GeoVax Revenue and Competitors
Estimated Revenue & Valuation
- GeoVax's estimated annual revenue is currently $3M per year.
- GeoVax's estimated revenue per employee is $77,500
- GeoVax's total funding is $28M.
Employee Data
- GeoVax has 39 Employees.
- GeoVax grew their employee count by 34% last year.
GeoVax's People
Name | Title | Email/Phone |
---|---|---|
1 | Chairman, President & CEO, GeoVax Labs, Inc. | Reveal Email/Phone |
2 | CFO | Reveal Email/Phone |
3 | VP, Quality Systems and Compliance | Reveal Email/Phone |
4 | VP, Business Development | Reveal Email/Phone |
5 | VP, Head Quality | Reveal Email/Phone |
6 | Head Commercial Development & Operations | Reveal Email/Phone |
7 | Director Vector Development | Reveal Email/Phone |
8 | Executive Medical Director, Oncology | Reveal Email/Phone |
9 | Director, Clinical Operations | Reveal Email/Phone |
10 | Director, Vaccine Development | Reveal Email/Phone |
GeoVax Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $0.9M | 6 | 0% | N/A | N/A |
#2 | $2M | 13 | -13% | N/A | N/A |
#3 | $3.1M | 20 | 18% | $13M | N/A |
#4 | $1.1M | 7 | 0% | N/A | N/A |
#5 | $20.8M | 134 | 5% | $0.07B | N/A |
#6 | $3.7M | 24 | -8% | N/A | N/A |
#7 | $0.8M | 5 | 0% | N/A | N/A |
#8 | $163.8M | 1057 | 4% | N/A | N/A |
#9 | $0.9M | 6 | -14% | N/A | N/A |
#10 | $7.9M | 51 | 2% | N/A | N/A |
What Is GeoVax?
GeoVax is a Biotechnology company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus - AIDS) and other infectious agents. Our goals include: developing AIDS vaccines for global markets, manufacturing and testing these vaccines under GMP/GLP conditions (FDA guidelines), conducting phase I/II and III human trials for vaccine safety and effectiveness and obtaining regulatory approval of these vaccines in the USA and specified international markets. Outstanding preclinical results: GeoVax DNA/MVA vaccine protected 96% of non-human primates for over 3½ yrs. To our knowledge, this level of protection has not been achieved by other candidate vaccines.
keywords:Biotechnology$28M
Total Funding
39
Number of Employees
$3M
Revenue (est)
34%
Employee Growth %
N/A
Valuation
N/A
Accelerator
GeoVax News
GeoVax Labs, a biotechnology company focused on the development of vaccines and immunotherapies, announced on April 26, 2022 that the US...
GeoVax Labs, a biotechnology company focused on the development of vaccines and immunotherapies, announced on April 26, 2022 that the US...
GeoVax's Unique Multi-Antigenic Vaccine Approach Designed to Provide Stronger, Broader Protection Against Malaria Atlanta, GA, April 26,...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $7.3M | 39 | 5% | N/A |
#2 | $10.6M | 40 | 8% | N/A |
#3 | $10.5M | 40 | 3% | N/A |
#4 | $9.3M | 43 | 34% | N/A |
#5 | $7.6M | 43 | 19% | N/A |